

CITATION REPORT

List of articles citing

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

DOI: 10.1007/s00262-011-1028-0

Cancer Immunology, Immunotherapy, 2011, 60, 1419-30.

Source: <https://exaly.com/paper-pdf/51340910/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
484	Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. 2011 , 2011, 734036		28
483	The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. 2012 , 3, 270		52
482	Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. 2012 , 18, 5212-23		80
481	Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. 2012 , 132, 2642-51		51
480	Myeloid cells: Prime drivers of tumor progression. 2012 , 1, 1360-1367		11
479	Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. 2012 , 1, 201-204	6	
478	The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. 2012 , 1, 717-725		109
477	TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. 2012 , 35, 502-12		38
476	Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon- γ TLR-9 agonist and GM-CSF with peptide vaccination. 2012 , 35, 702-10		56
475	Myeloid-derived suppressor cells in cancer patients: a clinical perspective. 2012 , 35, 107-15		176
474	Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. 2012 , 189, 5533-40		140
473	On the armament and appearances of human myeloid-derived suppressor cells. 2012 , 144, 250-68		152
472	Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. 2012 , 72, 6338-43		90
471	Exploration of the correlations between interferon- γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon- γ mechanism inhibiting BIU-87 proliferation. 2012 , 188, 1346-53		17
470	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. 2012 , 1, 1323-1343		173
469	Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. 2012 , 131, 1951-62		58
468	Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1155-67	7.4	266

467	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. 2012 , 381, 14-22		146
466	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. 2012 , 33, 121-9		65
465	Regulatory dendritic cells in the tumor immunoenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 223-230	7-4	46
464	Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. 2012 , 132, 215-23		73
463	T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. 2013 , 139, 657-65		11
462	Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. 2013 , 1, 10		215
461	Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1421-30	7-4	191
460	Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1083-91	7-4	47
459	Inflammatory networks and immune surveillance of pancreatic carcinoma. 2013 , 25, 200-5		134
458	Tumor-induced Myeloid-derived Suppressor Cells. 2013 , 473-496		2
457	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1711-22	7-4	90
456	The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. 2013 , 190, 1372-9		40
455	Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. 2013 , 149, 1-10		10
454	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. 2013 , 59, 1007-13		127
453	Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. 2013 , 107, 1895-903		19
452	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. 2013 , 138, 105-15		491
451	Cancer-related inflammation. 2013 , 33 Suppl 1, S79-84		413
450	Tumor microenvironment and myeloid-derived suppressor cells. 2013 , 6, 169-77		90

449	Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1439-51	7.4	155
448	Myeloid-derived suppressor cells in cancer: recent progress and prospects. 2013 , 91, 493-502		168
447	The Tumor Immunoenvironment. 2013 ,		3
446	Tumor-released survivin induces a type-2 γ cell response and decreases cytotoxic T cell function, in vitro. 2013 , 6, 57-68		11
445	Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. 2013 , 19, 3404-15		360
444	Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 529-39	7.4	19
443	Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. 2013 , 4, 318		20
442	Down-regulation of PLC β -Eatenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. 2013 , 210, 2257-71		62
441	Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. 2013 , 19, 328-36		76
440	Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. 2013 , 73, 3007-18		267
439	Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. 2013 , 3, 49		114
438	Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. 2013 , 190, 794-804		186
437	Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. 2013 , 174, 45-52		96
436	Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. 2013 , 73, 2435-44		185
435	Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment. 2013 , 2, e24891		37
434	Immunotherapy for gastrointestinal malignancies. 2013 , 20, 32-42		25
433	Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. 2013 , 4, 3-11		80
432	Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. 2013 , 8, e55818		92

431	B cells promote tumor progression via STAT3 regulated-angiogenesis. 2013 , 8, e64159		82
430	Inflammation-related factors predicting prognosis of gastric cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4586-96	5.6	123
429	Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. 2014 , 05,		3
428	IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. <i>Oncotarget</i> , 2014 , 5, 8716 ² 28		111
427	Myeloid Derived Suppressor Cells: Fuel the Fire. 2014 , 3, e123		10
426	Complex role for the immune system in initiation and progression of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11160-81	5.6	85
425	Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. 2014 , 10, 3354-68		53
424	Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. 2014 , 21, 507-17		19
423	Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. <i>Frontiers in Immunology</i> , 2014 , 5, 67	8.4	8
422	Immunotherapy for Gastrointestinal Malignancies. 2014 , 05, 622-646		
421	Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. 2014 , 5, 52		57
420	Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. 2014 , 2, 812-21		97
419	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. 2014 , 2, 31		68
418	Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. 2014 , 37, 43-50		34
417	Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. 2014 , 3, e956579		42
416	A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. 2014 , 2014, 659294		80
415	Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. 2014 , 2014, 879897		96
414	The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. <i>Frontiers in Immunology</i> , 2014 , 5, 69	8.4	48

413	The immune network in pancreatic cancer development and progression. 2014 , 33, 2956-67		136
412	Inflammation and pancreatic cancer: disease promoter and new therapeutic target. 2014 , 49, 605-17		31
411	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 247-57	7.4	367
410	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 175-83	7.4	72
409	In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. 2014 , 135, 2107-17		51
408	Immunotherapy for solid tumors--a review for surgeons. 2014 , 187, 525-35		14
407	Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy. 2014 , 11, 311-8		26
406	Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. 2014 , 134, 1669-82		199
405	Clinical evaluation of systemic and local immune responses in cancer: time for integration. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 45-57	7.4	48
404	Tumor-induced perturbations of cytokines and immune cell networks. 2014 , 1845, 182-201		187
403	Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. 2014 , 20, 2049-55		53
402	Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 1273-84	7.4	1
401	RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. 2014 , 21, 1825-37		105
400	Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. 2014 , 75, 1128-37		49
399	p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. 2014 , 20, 4459-70		17
398	Myeloid-derived suppressor cell heterogeneity in human cancers. 2014 , 1319, 47-65		280
397	Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. 2014 , 106,		80
396	Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 513-28	7.4	144

395	Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice. 2014 , 41, 4069-76		14
394	Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. 2014 , 41, 174-84		128
393	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. 2014 , 40, 513-22		116
392	Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 889-900	74	34
391	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. 2014 , 124, 750-60		170
390	Novel pancreatic cancer vaccines could unleash the army within. 2014 , 21, 242-6		13
389	In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. 2015 , 126, 1138-48		59
388	The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. 2015 , 5, 18217		95
387	Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. 2015 , 74, 390-400		74
386	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. 2015 , 3, 54		30
385	Vasoactive intestinal peptide induces CD14+HLA-DR-/low myeloid-derived suppressor cells in gastric cancer. <i>Molecular Medicine Reports</i> , 2015 , 12, 760-8	2.9	8
384	Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy. 2015 , 15, 151-60		6
383	Plasticity of neutrophils reveals modulatory capacity. 2015 , 48, 665-75		30
382	Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients. 2015 , 62, 239-49		11
381	Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. 2015 , 128, 95-139		319
380	Vaccination approach to anti-angiogenic treatment of cancer. 2015 , 1855, 155-71		18
379	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 149-59	7.4	83
378	T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. 2015 , 56, 2498-504		15

377	A novel subset of B7-H3CD14HLA-DR myeloid-derived suppressor cells are associated with progression of human NSCLC. 2015 , 4, e977164		33
376	Repeated fine-needle aspiration of solid tumours in mice allows the identification of multiple infiltrating immune cell types. 2015 , 425, 102-107		1
375	The importance of the tumor microenvironment in the therapeutic management of cancer. 2015 , 15, 943-54		30
374	Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. 2015 , 75, 3456-65		85
373	Thymosin β promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1. 2015 , 464, 249-55		8
372	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. 2015 , 3, 1123-1129	98	
371	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 727-36	7-4	37
370	Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. 2015 , 17, 34		45
369	Immune Therapy in GI Malignancies: A Review. 2015 , 33, 1745-53		29
368	Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. 2015 , 4, e998519		67
367	Interleukin-2 Superfamily and Cancer. 2015 , 63-89		
366	Interleukin-17 Superfamily and Cancer. 2015 , 261-289		
365	Immunosuppression associated with chronic inflammation in the tumor microenvironment. 2015 , 36, 1085-93		192
364	A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. 2016 , 28, 87-97		17
363	Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. 2015 , 32, 847-56		54
362	Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity. 2015 , 195, 5237-50		54
361	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1609-21	7-4	31
360	TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. 2015 , 212, 2077-94		104

359	CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer. 2015 , 75, 4074-85			82
358	Innate Lymphoid Cells: Roles In Tumour Genesis And Progression. 2015 , 16, 85-91			
357	Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. 2015 , 4, e1014242			47
356	Myeloid regulatory cells in tumor spreading and metastasis. 2015 , 220, 236-42			74
355	Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. 2016 , 41, 404-418			2
354	Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6619-28	5.6		41
353	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. <i>Oncotarget</i> , 2016 , 7, 4760-9	3.3		43
352	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. <i>Oncotarget</i> , 2016 , 7, 7940-51	3.3		45
351	Serum Cytokine Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. 2016 , 2016, 3064643			16
350	Role of the tumor microenvironment in pancreatic adenocarcinoma. 2016 , 21, 31-41			5
349	Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3		29
348	Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. 2016 , 11, e0154016			44
347	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. 2016 , 4,			187
346	Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. 2016 , 39, 81-9			48
345	Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. 2016 , 36, 442-53			17
344	Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. 2016 , 38 Suppl 1, E1068-74			93
343	The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type. 2016 , 69, 846-51			16
342	Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-β during Murine Colitis. 2016 , 17, 3219-3232			73

341	Tumor-Induced Myeloid-Derived Suppressor Cells. 2016 , 4,	21
340	Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. 2016 , 95, e5541	80
339	Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. 2016 , 16, 322	20
338	IKK γ /NFBp65 activated by interleukin-13 targets the autophagy-related genes LC3B and beclin 1 in fibroblasts co-cultured with breast cancer cells. 2016 , 11, 1259-1264	16
337	Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. 2016 , 15, 99-105	29
336	Protection against HPV-16-Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells. 2016 , 15, 1920-30	18
335	Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation. 2016 , 36, 1-8	8
334	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. 2016 , 11, 593-603	12
333	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. 2016 , 4, 592-9	38
332	Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. 2016 , 213, 827-40	82
331	Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. 2016 , 28, 187-96	181
330	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 715-25	7-4 47
329	Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. 2016 , 110, 25-34	15
328	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. 2016 , 22, 4848-4858	108
327	Gemcitabine reduces MDSCs, tregs and TGFB β 1 while restoring the teff/treg ratio in patients with pancreatic cancer. 2016 , 14, 282	102
326	Role of adenosine A2b receptor overexpression in tumor progression. 2016 , 166, 92-99	29
325	Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. 2016 , 18, 541-52	20
324	Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. 2016 , 10, 1305-16	19

323	Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF- β 2016 , 499, 9-22	19
322	Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges. 2016 , 35, 372-385	19
321	Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer. 2016 , 512-525	2
320	Current Status of Immunotherapy Treatments for Pancreatic Cancer. 2016 , 50, 836-848	10
319	The role of myeloid cells in cancer therapies. 2016 , 16, 447-62	363
318	Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. 2016 , 14, 151	25
317	A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. 2016 , 73, 4043-61	49
316	Kinetics of human myeloid-derived suppressor cells after blood draw. 2016 , 14, 2	28
315	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. 2016 , 4, 14	73
314	Myeloid-derived suppressor cells in gastrointestinal cancers: A systematic review. 2016 , 31, 1246-56	13
313	Innate lymphoid cells involve in tumorigenesis. 2016 , 138, 22-9	14
312	Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation. 2016 , 40, 47-51	48
311	Increased, but Functionally Impaired, CD14(+) HLA-DR(-/low) Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells. 2016 , 136, 798-808	18
310	Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. 2016 , 26, 381-9	39
309	Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype. 2016 , 196, 1132-45	65
308	Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. 2016 , 113, E319-27	62
307	Pancreatic cancer: Update on immunotherapies and algenpantucel-L. 2016 , 12, 563-75	22
306	Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. 2016 , 18, 1253-64	87

305	Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. 2016 , 107, 207-16		19
304	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. 2016 , 76, 2125-36		121
303	The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. 2016 , 37, 10427-33		52
302	The emerging role of myeloid-derived suppressor cells in lung diseases. 2016 , 47, 967-77		31
301	The tumor microenvironment in esophageal cancer. 2016 , 35, 5337-5349		169
300	The Microenvironment of Lung Cancer and Therapeutic Implications. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 890, 75-110	3.6	58
299	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. 2016 , 22, 2565-74		52
298	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. 2016 , 1865, 35-48		51
297	Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. 2016 , 380, 253-6		56
296	Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. <i>Advances in Experimental Medicine and Biology</i> , 2016 ,	3.6	1
295	Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. 2016 , 196, 1419-29		39
294	New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. 2016 , 113, 35-41		25
293	The immunobiology of myeloid-derived suppressor cells in cancer. 2016 , 37, 1387-406		63
292	Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 503-513	7.4	40
291	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 2017 , 110, 106-116		29
290	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. 2017 , 77, 1296-1309		46
289	Potential importance of B cells in aging and aging-associated neurodegenerative diseases. 2017 , 39, 283-294		10
288	Mature CD10 and immature CD10 neutrophils present in G-CSF-treated donors display opposite effects on T cells. 2017 , 129, 1343-1356		159

287	PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. 2017 , 115-146		
286	Radiotherapy in the age of cancer immunology: Current concepts and future developments. 2017 , 112, 1-10		16
285	Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay. 2017 , 35, 377-385		2
284	Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype. 2017 , 152, 89-101		35
283	CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. 2017 , 77, 3655-3665		165
282	T-cell programming in pancreatic adenocarcinoma: a review. 2017 , 24, 106-113		34
281	Tackling immunomonitoring in gastrointestinal cancer. 2017 , 29, 296-305		1
280	Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities. 2017 , 38, 449-455		11
279	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). 2017 , 23, 5034-5043		24
278	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K. 2017 , 77, 2607-2619		123
277	Unleashing the immune response against childhood solid cancers. 2017 , 64, e26548		5
276	Immunotherapy for Gastrointestinal Cancer. 2017 ,		0
275	MDSCs are induced after experimental blunt chest trauma and subsequently alter antigen-specific T cell responses. 2017 , 7, 12808		15
274	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. 2017 , 8, 593		104
273	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1437-1447	7-4	44
272	An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. 2017 , 20, 757-770		70
271	Drug-eluting scaffold inhibited in vivo pancreatic tumorigenesis by engaging murine CCR4CD8 T cells. 2017 , 158, 469-473		9
270	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. 2017 , 46, 994-1002		14

269	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 2017 , 5, 44		139
268	Friend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development. 2017 , 38, 29-38		35
267	The Diverse Biological Functions of Neutrophils, Beyond the Defense Against Infections. 2017 , 40, 311-323		46
266	Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer. 2017 , 23, 235-244		75
265	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 β , IL8, CXCL5, and Mip-1 α 2017 , 23, 2346-2355		101
264	Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. 2017 , 36, 1232-1244		102
263	Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. 2017 , 39, 347-355		25
262	Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. 2017 , 440, 12-18		12
261	Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. 2017 , 9, 59-64		24
260	Interleukin-6 -Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 1840	8.4	54
259	Enhanced circulating ILC2s and MDSCs may contribute to ensure maintenance of Th2 predominant in patients with lung cancer. <i>Molecular Medicine Reports</i> , 2017 , 15, 4374-4381	2.9	15
258	Chemotherapy and tumor microenvironment of pancreatic cancer. 2017 , 17, 68		58
257	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. 2017 , 5, 55		4
256	On the origin of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2017 , 8, 3649-3665	3.3	109
255	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. 2017 , 23, 235-246		9
254	Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?. 2017 , 9, 1798-1801		
253	IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3. <i>International Immunopharmacology</i> , 2018 , 59, 148-156	5.8	20
252	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. 2018 , 36, 405-412		30

251	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. 2018 , 11, 27-32	29
250	Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies. 2018 , 13, 157-173	19
249	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. 2018 , 35, 19-28	135
248	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. 2018 , 52, 241-252	9
247	B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. 2018 , 7, e1393599	10
246	Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. 2018 , 40, 91-97	22
245	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. 2018 , 67, 320-332	255
244	Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections. 2018 , 223, 432-442	24
243	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives. 2018 , 66, 113-123	26
242	Emerging trends in the immunotherapy of pancreatic cancer. 2018 , 417, 35-46	61
241	Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. 2018 , 9, 1014-1026	25
240	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. 2018 , 10, 1276-1279	3
239	Similarities in Blood Mononuclear Cell Membrane Phospholipid Profiles During Malignancy. 2018 , 6,	
238	The Yin and Yang of Myeloid Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 2776	8.4 39
237	Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. 2018 , 7, e1509821	8
236	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. 2018 , 13, 599-609	12
235	A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. 2018 , 6, 100	26
234	Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. <i>Cancers</i> , 2018 , 10,	6.6 21

233	Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. 2018 , 35, 158		6
232	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. 2018 , 9, 196-207		13
231	Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction. 2018 , 45, 84-94		2
230	Immune suppression and reversal of the suppressive tumor microenvironment. 2018 , 30, 445-454		70
229	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. 2018 , 2, 274-281		87
228	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells - is a new era coming?. 2018 , 55, 376-407		9
227	Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies. 2018 , 7, e1494113		41
226	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. 2018 , 2018, 9740357		9
225	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <i>Frontiers in Immunology</i> , 2018 , 9, 398	8.4	274
224	Granulocytic Myeloid-Derived Suppressor Cells (GR-MDSC) in Breast Milk (BM); GR-MDSC Accumulate in Human BM and Modulate T-Cell and Monocyte Function. <i>Frontiers in Immunology</i> , 2018 , 9, 1098	8.4	19
223	The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. <i>Frontiers in Immunology</i> , 2018 , 9, 1188	8.4	26
222	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2018 , 9, 1310	8.4	260
221	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. 2018 , 6, 65		70
220	CD45CD33CD11b myeloid-derived suppressor cells suppress CD8 T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. 2018 , 9, 763		29
219	The Microenvironment in Epstein-Barr Virus-Associated Malignancies. 2018 , 7,		29
218	Strategies to increase cardioprotection through cardioprotective chemokines in chemotherapy-induced cardiotoxicity. 2018 , 269, 276-282		15
217	Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. 2018 , 103, 115-124		36
216	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. 2018 , 6,		5

215	Perioperative blood transfusion is associated with an increased risk for post-surgical infection following pancreaticoduodenectomy. 2019 , 21, 1577-1584		9
214	The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets. 2019 , 48, 11-23		15
213	Inhibiting PI3 kinase- γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. 2019 , 309, 173-180		27
212	T Regulatory CD4CD25FoxP3 Lymphocytes in the Peripheral Blood of Left-Sided Colorectal Cancer Patients. 2019 , 55,		5
211	The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?. 2019 , 47, 4149-4158		16
210	Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
209	Unconventional T Cells in the Pancreatic Tumor Microenvironment: Thinking Outside the Box. 2019 , 9, 1164-1166		2
208	Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. 2019 , 21, 103		25
207	Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. 2019 , 8, 1652532		39
206	Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	17
205	Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer. 2019 , 9, 855		31
204	MDSCs in pregnancy: Critical players for a balanced immune system at the feto-maternal interface. 2019 , 346, 103990		9
203	Targeting Pancreatic Stellate Cells in Cancer. 2019 , 5, 128-142		56
202	Immunostimulatory functions of adoptively transferred MDSCs in experimental blunt chest trauma. 2019 , 9, 7992		8
201	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. 2019 , 38, 162		66
200	The transcriptional profile of circulating myeloid derived suppressor cells correlates with tumor development and progression in mouse. 2019 , 20, 589-598		4
199	Role of the tumor microenvironment in pancreatic cancer. 2019 , 3, 130-137		53
198	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. <i>Frontiers in Immunology</i> , 2019 , 10, 193	8.4	61

197	Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell Interaction. 2019 , 19, 81-92	7
196	Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?. 2019 , 8, 61	8
195	Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. 2019 , 9, 1359	16
194	Increased Adiposity Enhances the Accumulation of MDSCs in the Tumor Microenvironment and Adipose Tissue of Pancreatic Tumor-Bearing Mice and in Immune Organs of Tumor-Free Hosts. 2019 , 11,	13
193	The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. 2019 , 2019, 6240505	5
192	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. 2019 , 68, 159-171	151
191	The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. 2019 , 189, 44-57	32
190	T-cell-Secreted TNF α Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. 2019 , 79, 346-359	30
189	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. 2019 , 70, 449-457	60
188	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. 2019 , 7, 428-442	59
187	Graphene quantum dots-functionalized multi-walled carbon nanotubes as nanocarriers in electrochemical immunosensing. Determination of IL-13 receptor α in colorectal cells and tumor tissues with different metastatic potential. 2019 , 284, 711-722	37
186	IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF- β Collagen Type I, and PD-L1/PD-1. 2019 , 202, 787-798	16
185	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. 2019 , 20, 357-366	6
184	Dysregulation of key microRNAs in pancreatic cancer development. 2019 , 109, 1008-1015	28
183	Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer. 2020 , 38, 5.e17-5.e23	1
182	Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells. 2020 , 12, 2752-2763	4
181	The Immune Microenvironment in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 50
180	Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice. 2020 , 10, 11257	7

179	Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. 2020 , 111, 3132-3141		51
178	Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors. 2020 , 17, 431-447		6
177	Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche. 2020 , 12, 5857-5879		7
176	Translational Pancreatic Cancer Research. <i>Molecular and Translational Medicine</i> , 2020 ,	0.4	1
175	ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. 2020 , 6,		6
174	Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes. 2020 , 12, 1273-1285		4
173	Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients. 2020 , 10, 1530		3
172	Myeloid-Derived Suppressor Cells Promote the Progression of Primary Membranous Nephropathy by Enhancing Th17 Response. <i>Frontiers in Immunology</i> , 2020 , 11, 1777	8.4	3
171	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
170	Apigenin Increases SHIP-1 Expression, Promotes Tumoricidal Macrophages and Anti-Tumor Immune Responses in Murine Pancreatic Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
169	Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer. 2020 , 11, 576		6
168	Myeloid Cell-Derived Arginase in Cancer Immune Response. <i>Frontiers in Immunology</i> , 2020 , 11, 938	8.4	91
167	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	2
166	What are the effects of IL-1[rs1143634), IL-17A promoter (rs2275913) and TLR4 (rs4986790) gene polymorphism on the outcomes of infection with H. pylori within as Iranian population; A systematic review and meta-analysis. 2020 , 20, 100735		11
165	Interleukins 4 and 13 and Their Receptors Are Differently Expressed in Gastrointestinal Tract Cancers, Depending on the Anatomical Site and Disease Advancement, and Improve Colon Cancer Cell Viability and Motility. <i>Cancers</i> , 2020 , 12,	6.6	7
164	Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. 2020 , 295, 203-219		17
163	Carcinogenesis of Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2020 , 158, 2072-2081	13.3	33
162	Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. 2020 , 8, 172		4

161	Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 3111	8.4	14
160	CD200 promotes immunosuppression in the pancreatic tumor microenvironment. 2020 , 8,		18
159	Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience. 2020 , 61, 1645-1652		8
158	Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2019 , 10, 3070	8.4	47
157	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020 , 9,	7.9	14
156	Microenvironmental Determinants of Pancreatic Cancer. 2020 , 100, 1707-1751		62
155	Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas. 2020 , 15, e0231833		4
154	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. 2021 , 18, 829-841		7
153	Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1619-1634	7.4	13
152	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. 2021 , 27, 1069-1081		20
151	The tumour immune landscape and its implications in cutaneous melanoma. 2021 , 34, 529-549		8
150	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. 2021 , 10, 1956143		4
149	Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells. 2021 , 17, 1093-1100		2
148	Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. 2021 , 21, 212		2
147	Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
146	Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. 2021 , 361, 104280		5
145	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. 2021 , 44, 261-278		1
144	The role of myeloid-derived suppressor cells in gastrointestinal cancer. 2021 , 41, 442-471		2

143	Low level of stromal lectin-like oxidized LDL receptor 1 and CD8 cytotoxic T-lymphocytes indicate poor prognosis of colorectal cancer. 2021 , 4, e1364		1
142	Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next?. 2021 , 331, 246-259		8
141	Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. 2021 , 13,		5
140	The tumour immune microenvironment in oesophageal cancer. 2021 , 125, 479-494		2
139	Advances in research of extracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. 2021 , 29, 421-434		
138	Nomogram based on immune scores for predicting the survival of patients with esophageal squamous cell carcinoma. 2021 , 49, 3000605211009697		0
137	Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction. <i>Frontiers in Immunology</i> , 2021 , 12, 651056	8.4	6
136	Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis. 2021 , 363, 104317		3
135	The Neutrophil-to-Monocyte Ratio and Platelet-to-White Blood Cell Ratio Represent Novel Prognostic Markers in Patients with Pancreatic Cancer. 2021 , 2021, 6693028		3
134	Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021 , 12, 6332054	8.4	13
133	Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. 2021 , 13, 312-331		1
132	Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. <i>Cancers</i> , 2021 , 13,	6.6	10
131	Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
130	Comparing the frequency of CD33 pSTAT3 myeloid-derived suppressor cells and IL-17 lymphocytes in patients with prostate cancer and benign prostatic hyperplasia. 2021 , 45, 2086-2095		1
129	A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer. 2021 , 17, e2101208		7
128	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
127	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. 2021 , 98, 102219		1
126	Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. 2021 , 125, 1068-1079		2

125	CD73 expression in myeloid-derived suppressor cells is correlated with clinical stages in head and neck squamous cell carcinomas. 2021 , 9, 1148		1
124	Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4045-4087	5.6	4
123	Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. 2021 , 277, 119627		10
122	GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. 2021 , 9,		5
121	Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression. 2021 , 165, 164-173		10
120	Pancreatic Cancer and Immunotherapy: A Clinical Overview. <i>Cancers</i> , 2021 , 13,	6.6	7
119	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. <i>Cancers</i> , 2021 , 13,	6.6	5
118	Myeloidderived peripheral blood suppressor cells at haematopoietic stem cell mobilisation in multiple myeloma patients. 2021 , 66, 218-230		1
117	Tumor Microenvironment of Esophageal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
116	Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer. 2022 , 409-435		1
115	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. <i>Cancers</i> , 2021 , 13,	6.6	5
114	The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. 2020 , 10, 621937		15
113	Myeloid-derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma. <i>Scandinavian Journal of Immunology</i> , 2021 , 93, e13021	3.4	2
112	Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review. 2021 , 13, 1-11		4
111	Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	10
110	Immune determinants of Barrett's progression to esophageal adenocarcinoma. 2021 , 6,		4
109	Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1224, 35-51	3.6	4
108	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2101-2112	7.4	8

107	The ratio of HLA-DR and VNN2 expression on CD14 myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients. 2017 , 134, 189-196	11
106	Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis. 2020 , 125, 109864	5
105	Tumor-Induced Myeloid-Derived Suppressor Cells. 833-856	1
104	STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. 2013 , 123, 1580-9	349
103	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. 2013 , 123, 4464-78	214
102	Vaccine-induced myeloid cell population dampens protective immunity to SIV. 2014 , 124, 2538-49	49
101	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. 2015 , 125, 3365-76	351
100	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. 2017 , 127, 2916-2929	104
99	Role of prostanoids in gastrointestinal cancer. 2018 , 128, 2732-2742	67
98	Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. 2013 , 8, e54824	39
97	Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. 2014 , 9, e87705	220
96	Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. 2014 , 9, e96565	81
95	Infiltration of alternatively activated macrophages in cancer tissue is associated with MDSC and Th2 polarization in patients with esophageal cancer. 2014 , 9, e104453	39
94	The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis. 2016 , 11, e0164514	95
93	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. 2017 , 13, e1006395	22
92	Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. 2019 , 24, 105-118	3
91	CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. 2020 , 12, 502-517	16
90	Interleukin-13 receptor α 2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. <i>Oncotarget</i> , 2016 , 7, 49281-49288	3-3 14

89	Prognostic value of PDL1 expression in pancreatic cancer. <i>Oncotarget</i> , 2016 , 7, 71198-71210	3.3	59
88	The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. <i>Oncotarget</i> , 2017 , 8, 95083-95094	3.3	14
87	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. <i>Oncotarget</i> , 2017 , 8, 102721-102738	3.3	29
86	Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. <i>Oncotarget</i> , 2017 , 8, 97822-97834	3.3	9
85	IL-1RT1 signaling antagonizes IL-11 induced STAT3 dependent cardiac and antral stomach tumor development through myeloid cell enrichment. <i>Oncotarget</i> , 2015 , 6, 679-95	3.3	4
84	Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. <i>Oncotarget</i> , 2015 , 6, 44509-22	3.3	11
83	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 351	5.7	22
82	Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	18
81	Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5454-61	5.6	21
80	Cancer immunotherapy for pancreatic cancer utilizing E ₉ gal epitope/natural anti-Gal antibody reaction. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11396-410	5.6	10
79	Ambiguous roles of innate lymphoid cells in chronic development of liver diseases. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1962-1977	5.6	6
78	p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. <i>World Journal of Gastroenterology</i> , 2018 , 24, 3709-3723	5.6	21
77	Role of different immune cells and metabolic pathways in modulating the immune response in pancreatic cancer (Review). <i>Molecular Medicine Reports</i> , 2020 , 22, 4981-4991	2.9	3
76	Myeloid-Derived Suppressor Cells Recruited by Chemokine (C-C Motif) Ligand 3 Promote the Progression of Breast Cancer via Phosphoinositide 3-Kinase-Protein Kinase B-Mammalian Target of Rapamycin Signaling. <i>Journal of Breast Cancer</i> , 2020 , 23, 141-161	3	9
75	Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice. <i>Journal of Cancer Science & Therapy</i> , 2013 , 5, 291-299	5	10
74	Detection and clinical significance of DNA repair gene ERCC8 tag SNPs in gastric cancer. <i>Turkish Journal of Gastroenterology</i> , 2018 , 29, 392-396	1	2
73	Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer. <i>Clinics</i> , 2013 , 68, 858-64	2.3	3
72	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. <i>Cells</i> , 2021 , 10,	7.9	2

71	Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. <i>Cancers</i> , 2021 , 13,	6.6	5
70	Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies. <i>Inflammopharmacology</i> , 2021 , 29, 1613-1624	5.1	1
69	Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy. <i>Biomarker Research</i> , 2021 , 9, 77	8	3
68	Graft-Versus-Host Disease Prevention by -Generated Myeloid-Derived Suppressor Cells Is Exclusively Mediated by the CD11b+CD11c+ MDSC Subpopulation. <i>Frontiers in Immunology</i> , 2021 , 12, 754316	8.4	0
67	Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. <i>Gastroenterology</i> , 2021 , 161, 1813-1829	13.3	10
66	IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients. <i>Scandinavian Journal of Immunology</i> , 2021 , 94, e13107	3.4	2
65	Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 362	21	26
64	Approaches to Immunologic Monitoring of Clinical Trials. 2013 , 663-694		
63	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer. 2013 , 707-723		
62	Innate and Adaptive Immune Responses to Cancer. 2014 , 81-121		1
61	Myeloid-Derived Suppressor Cells in Cancer. 2014 , 3-17		
60	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. <i>AIMS Public Health</i> , 2015 , 2, 86-114	1.9	1
59	Neoplasia of the Gastrointestinal Tract. 587-616		
58	Modern concepts of factors for gastric cancer progression. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2016 , 5, 82	0.2	
57	Targeting the Tumor Microenvironment. 2018 , 235-256		
56	Innate and Adaptive Immune Responses to Cancer. 2019 , 111-159		1
55	Pancreatic Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1296, 243-253.6		1
54	Clinical Impact of Myeloid-Derived Suppressor Cells, Lymphocyte Subsets, and Neutrophil-to-Lymphocyte Ratio in Patients with Colorectal Cancer. <i>Laboratory Medicine Online</i> , 2020 , 10, 75	0.2	

53	Targeting the Immune System in Pancreatic Cancer. <i>Molecular and Translational Medicine</i> , 2020 , 203-218.	0.4	
52	Discovering the route from inflammation to pancreatic cancer. <i>Minerva Gastroenterologica E Dietologica</i> , 2012 , 58, 283-97	1.6	31
51	Expansion of myeloid-derived suppressor cells from peripheral blood decreases after 4-week antiviral treatment in patients with chronic hepatitis C. <i>International Journal of Clinical and Experimental Medicine</i> , 2014 , 7, 998-1004		6
50	Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014 , 7, 3181-92		49
49	Enhanced circulating ILC2s accompany by upregulated MDSCs in patients with asthma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 3568-79	1.4	4
48	Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 752346	5.7	2
47	Myeloid-Derived Suppressor Cells in Solid Tumors.. <i>Cells</i> , 2022 , 11,	7.9	3
46	Nanozyme-Based Enhanced Cancer Immunotherapy.. <i>Tissue Engineering and Regenerative Medicine</i> , 2022 , 1	4.5	4
45	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.. <i>Frontiers in Immunology</i> , 2022 , 13, 781660	8.4	2
44	The association of dietary fibre intake and the IL13 rs20541 polymorphism with the risk of gastric cancer: a case-control study in Korea.. <i>European Journal of Clinical Nutrition</i> , 2022 ,	5.2	
43	Myeloid-Derived Suppressor Cells (MDSC) in the Umbilical Cord Blood: Biological Significance and Possible Therapeutic Applications.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
42	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.. <i>Pharmacology & Therapeutics</i> , 2022 , 108114	13.9	2
41	Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.. <i>British Journal of Anaesthesia</i> , 2022 ,	5.4	2
40	Identification of a DNA repair 9-gene signature for the overall survival prediction of pancreatic cancer.. <i>Annals of Diagnostic Pathology</i> , 2022 , 57, 151883	2.2	0
39	Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.. <i>Cancers</i> , 2021 , 13,	6.6	3
38	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.. <i>International Immunopharmacology</i> , 2022 , 106, 108628	5.8	0
37	image_1.PDF. 2018 ,		
36	Image_1.TIF. 2020 ,		

35 Image_2.TIF. 2020,

34 Image_3.TIF. 2020,

33 Image_4.TIF. 2020,

32 Image_5.TIF. 2020,

31 Image_6.TIF. 2020,

30 Video_1.AVI. 2020,

29 Video_2.AVI. 2020,

28 Video_3.MP4. 2020,

27 Video_4.MP4. 2020,

26 Video_5.MP4. 2020,

25 Video_6.MP4. 2020,

24 Video_7.AVI. 2020,

23 Data_Sheet_1.docx. 2020,

22 Table_1.docx. 2020,

21 Data_Sheet_1.PDF. 2020,

20 Data_Sheet_1.PDF. 2019,

19 Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN- γ /TNF- α and PD-1/PD-L1 in comparison to established serum tumor markers. *Journal of Cancer Research and Clinical Oncology*, 4.9 ○

18 The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. *International Journal of Molecular Sciences*, 2022, 23, 7066 6.3 ○

17	Antibody-Based Approaches to Target Pancreatic Tumours. <i>Antibodies</i> , 2022 , 11, 47	7	2
16	Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets. 497-510		0
15	Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy. 13,		0
14	DCLK1 suppresses tumor-specific cytotoxic T lymphocyte function through recruitment of MDSCs via the CXCL1-CXCR2 axis. 2022 ,		0
13	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. 2022 , 11,		2
12	The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer. 62-69		0
11	MDSCs in pregnancy and pregnancy-related complications: an update.		0
10	Cancer cell-derived type I interferons instruct tumor monocyte polarization. 2022 , 41, 111769		0
9	Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients. 2022 , 13, 1341-1349		0
8	Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. 2023 , 15, 176		1
7	Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. 12,		0
6	Tumor immunology. 2023 , 245-452		0
5	A High-Throughput Colorimetric Microplate Assay for Determination of Plasma Arginase Activity. 2023 , 273-286		0
4	Lnc-17Rik promotes the immunosuppressive function of Myeloid-Derived suppressive cells in esophageal cancer. 2023 , 385, 104676		0
3	Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer. 2023 , 24, 7359		0
2	In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators. 14,		0
1	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. 2023 , 173-192		0